Biotech's That Are Heating Up Posted: Mar 31, 2017 2:37 PM PDT The biotech sector is beginning to see a comeback after suffering a decline due to drug pricing issues raised during the U.S. Presidential election. However, the sector has gained 10.3 % in 2017, outperforming the S&P 500, which is up 6.3% YTD. A more pro-business administration, a faster drug approval process and the removal of outdated regulations that drive up costs and slow innovation are expected to benefit the biotech sector moving forward.
A very important strategy in biotech is investing at the right time and in the right companies. One segment of the biotech sector that could be ripe for investment is electroceuticals/bioelectronics, which are medical devices that use electrical, electromagnetic, mechanical or light stimulation to affect electrical signaling in tissues.
A prime example of the kind of gains that can be realized in this segment of the sector is Pulse Biosciences (PLSE), which has seen its share price nearly quadruple since February on news that healthcare executives and entrepreneurs Robert Duggan and Dr. Maky Zanganeh had acquired a combined interest of 17.1% and the recent submission by the company of its FDA 510(k) application for its PulseTx™ System. PLSE's technology, Nano-Pulse Stimulation (NPS) uses nano second electric pulses to illicit an immune response for the treatment of cancer.
Another biotech that seems to be following the same trajectory as PLSE is Endonovo Therapeutics (ENDV), which uses Time Varying Electromagnetic Pulses to illicit an anti-inflammatory response to treat inflammatory and vascular diseases. In situations like cancer, where the immune response is too low, technologies like PLSE's Nano-Pulse Stimulation, which illicit an immune response to treat cancer may be the future. Whereas, in situations where the immune response is too strong, such as sepsis or following ischemia/reperfusion injury, ENDV's technology may be the future treatment modality.
On March 23rd, ENDV announced it had filed a non-provisional patent with the United States and Trademark Office (USPTO) on a method to treat tissues and organs using its Immunotronics™ technology. With a non-provisional patent application filed, you will want to keep your eye on ENDV as they progress on a method to treat tissues and organs using its non-invasive electroceutical technology.
“We are very excited about our new generation of non-invasive electroceuticals developed specifically to target vascular diseases and ischemic injuries," stated ENDV Chairman and CEO, Alan Collier.
The Company is evaluating the therapeutic potential of its new electroceutical technology in treatment and prevention of heart failure following myocardial infarction. ENDV anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017.
Furthermore, like PLSE, Endonovo Therapeutics has attracted the attention and investment of a strategic healthcare investor to finance the development of its pipeline targeting vascular diseases and ischemia/reperfusion injuries and uplist its common stock onto a national stock exchange.
News 
Market Data 
Discover 
